<DOC>
	<DOCNO>NCT00292955</DOCNO>
	<brief_summary>The anti-tumor activity cetuximab prior chemoradiotherapy safety tolerability cetuximab concurrent chemoradiation determine woman locally advance metastatic cervical carcinoma .</brief_summary>
	<brief_title>Cetuximab , Cisplatin , Radiotherapy Women With Locally Advanced Cervical Carcinoma</brief_title>
	<detailed_description>- Women Federation Gynecology Obstetrics ( FIGO ) Clinical Stage IB2-IVB carcinoma cervix - Baseline cervical biopsy , blood sample , FDG-PET/computed tomography ( CT ) scan - Cetuximab 400 mg/m2 day 1 follow cetuximab 250 mg/m2 day 8 15 - Repeat cervical biopsy FDG-PET/CT scan follow cetuximab monotherapy - Radiation weekly cisplatin 40 mg/m2 cetuximab 250 mg/2 6 week - Cetuximab 250 mg/m2 weekly 12 week - Repeat cervical biopsy ( tumor present ) FDG-PET/CT scan completion therapy - Follow tumor recurrence survival</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patients must sign Washington University , Human Studies Committee ( HSC ) approve , inform consent . 2 . Patients must primary , histologically document FIGO Clinical Stage IB2IVB invasive carcinoma uterine cervix measurable disease amendable repeat biopsy . 3 . Patients must ECOG performance status 0 , 1 , 2 study entry . 4 . Patients , 18 year old , must either child bear potential negative pregnancy test within 7 day treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Women breast feed study . 5 . Women must primary diagnosis invasive carcinoma uterine cervix . Men exclude study consequence diagnosis investigate . 6 . Patients must previous treatment invasive carcinoma uterine cervix . 7 . Patients must newly diagnose locally advanced metastatic cervical carcinoma . 8 . Bone marrow function : absolute neutrophil count ( ANC ) ≥ 1,500/mcl ; platelet &gt; 100,000/mcl . 9 . Renal function : creatinine ≤ 2.0 mg/dl . 10 . Hepatic function : bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; SGOT ≤ 2.5 time upper limit normal ( ULN ) . 11 . Patients ureteral obstruction must treat stent nephrostomy tube placement . 12 . Patients neuropathy ( sensory motor ) must ≤ grade 1 defined National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 ( June 10 , 2003 ) . 1 . Acute hepatitis know HIV . 2 . Active uncontrolled infection . 3 . Significant history uncontrolled cardiac disease i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . 4 . Prior therapy specifically directly target EGFR pathway . 5 . Prior severe infusion reaction monoclonal antibody . 6 . Any concurrent chemotherapy indicate study protocol investigational agent ( ) . 7 . A serious uncontrolled medical disorder opinion Investigator would impair ability subject receive protocol therapy . 8 . Unresolved ureteral obstruction . 9 . Renal abnormality , pelvic kidney , horseshoe kidney , renal transplant , would require modification radiation field . 10 . Known documented brain metastasis . 11 . Any concurrent malignancy nonmelanoma skin cancer . ( Patients previous malignancy without evidence disease ≥ 5 year allow enter trial ) . 12 . Prior radiation therapy abdomen and/or pelvis 13 . Incarceration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cervical Cancer , Cetuximab , Phase II Clinical Trials</keyword>
	<keyword>Stage IB2-IVB Carcinoma Cervix</keyword>
</DOC>